The short answer
Ginkgo can be a concern during warfarin treatment. A large observational study found an association with bleeding, and warfarin labeling warns of potentially additive effects. Small controlled studies found no significant change in INR or warfarin response for their tested products. The evidence supports caution but does not provide a reliable risk estimate for every ginkgo preparation.
What this answer covers
Oral Ginkgo biloba supplements with oral warfarin. Tested extracts, leaf products and mixed supplements are not assumed to be interchangeable.
- Supplement or preparation
- Ginkgo
- Medication ingredient
- warfarin
What does the evidence show?
A Veterans Administration record study associated documented ginkgo co-use with bleeding after statistical adjustment. This is a real-world signal, but supplement dose, adherence and exact start dates were not reliably established. In contrast, a crossover trial in stable warfarin patients using ginkgo 100 mg/day and a separate healthy-volunteer study found no significant change in measured warfarin response. The studies answer different questions: short controlled INR measurements do not fully resolve long-term bleeding risk in more complex patients.
Which forms and conditions matter?
A plant name does not specify extract standardization or active constituent content. The evidence from one characterized preparation should not be applied to every ginkgo product. Bleeding may also involve platelet effects not captured completely by INR, so a normal INR alone is not a blanket clearance to add a supplement.
What should I discuss with my care team?
Ask the anticoagulation clinician to review ginkgo before starting, stopping or switching a product. Give the clinician the supplement label and a complete list of medicines, particularly other products that affect bleeding. The inspected studies do not establish a dose-spacing strategy that prevents possible platelet or anticoagulant effects. Warfarin changes should be made by the treating team.
How certain is the answer?
The observed association is not proof of causation or an individual risk prediction. The small trials cannot exclude rare hemorrhage and do not represent every formulation or high-risk patient. The article therefore presents both the bleeding signal and neutral trials rather than choosing only the evidence that supports a stronger headline.
Evidence and practical considerations
Side effects & toxicity
Ginkgo can be a concern during warfarin treatment. A large observational study found an association with bleeding, and warfarin labeling warns of potentially additive effects. Small controlled studies found no significant change in INR or warfarin response for their tested products. The evidence supports caution but does not provide a reliable risk estimate for every ginkgo preparation.
- Exact scope
- Oral Ginkgo biloba supplements with oral warfarin. Tested extracts, leaf products and mixed supplements are not assumed to be interchangeable. with Oral warfarin, including warfarin sodium tablets with the warfarin active moiety.
- Medication form and route
- oral warfarin
- Timing or duration
- Study-specific durations are described in each source exposure; no universally safe exposure duration has been established.
What remains uncertain
- The observed association is not proof of causation or an individual risk prediction. The small trials cannot exclude rare hemorrhage and do not represent every formulation or high-risk patient. The article therefore presents both the bleeding signal and neutral trials rather than choosing only the evidence that supports a stronger headline.
Factors that may matter: Exact supplement preparation and other ingredients; Starting, stopping or changing supplement intake; Baseline anticoagulation control and clinician-supervised monitoring.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral warfarin sodium tablets.
The label advises closer INR monitoring when botanicals are started or stopped, identifies variable botanical composition and lists selected potential interactions. Vitamin K intake should remain consistent.
How this applies: Oral warfarin sodium has warfarin as its active moiety. Label-level botanical and vitamin K monitoring advice applies; it is not proof of this exact supplement effect. Oral Ginkgo biloba supplements with oral warfarin. Tested extracts, leaf products and mixed supplements are not assumed to be interchangeable.
Regulatory precautions do not quantify the incidence for every exact preparation or prove an interaction for an unlisted ingredient. Warfarin sodium is bridged to the warfarin active moiety only for the oral product.
Source 2: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 24 outpatients on stable long-term warfarin; three withdrew.
INR remained stable and mean weekly warfarin dose did not differ significantly across periods.
How this applies: This crossover tested both Ginkgo biloba and coenzyme Q10 separately with warfarin. Use only the arm corresponding to the package supplement; no evidence for another botanical. Exact package scope: Oral Ginkgo biloba supplements with oral warfarin. Tested extracts, leaf products and mixed supplements are not assumed to be interchangeable.
Small short crossover with adjusted warfarin doses; cannot exclude rare events, different products or larger doses.
Source 3: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 12 healthy men in a randomized open-label crossover study.
Neither tested herb significantly changed warfarin clearance, INR response or platelet aggregation.
How this applies: Use only the ginkgo or ginger arm for the corresponding botanical. The ginger preparation in the abstract does not establish equivalence to this exact root-powder node. Exact package scope: Oral Ginkgo biloba supplements with oral warfarin. Tested extracts, leaf products and mixed supplements are not assumed to be interchangeable.
Healthy volunteers, single warfarin exposure and short follow-up; precise product strengths are not provided in the retrieved abstract. Does not establish safety during chronic anticoagulation or for every root powder or extract.
Source 4: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Large Veterans Administration electronic-record cohort of warfarin users.
Adjusted analysis associated ginkgo co-use with bleeding events, hazard ratio 1.38 (95% confidence interval 1.20 to 1.58).
How this applies: Direct observational Ginkgo biloba and warfarin exposure analysis. Risk association is not a randomized causal estimate. Exact package scope: Oral Ginkgo biloba supplements with oral warfarin. Tested extracts, leaf products and mixed supplements are not assumed to be interchangeable.
Observational signal with uncertain supplement adherence, dose and timing; residual confounding and record-extraction error remain possible.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original evidence and contradictory findings assessed for this exact pair. Article drafted and existing statements adjudicated. Clinical sign-off has not been recorded. | |
| Research summary published |
Article revision: e7afb6d4c985bed7
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.